Drug Discovery
ByIs Eli Lilly’s $450 Million AI Investment in 2025 Set to Transform Drug Discovery, R&D, and Commercialization?
Global – December 31, 2025 — Eli Lilly and Company significantly expanded its artificial intelligence (AI) investments in…
Is Pfizer’s $500 Million AI Investment in 2025 Poised to Redefine Drug Discovery and Commercialization?
Global – December 31, 2025 — Pfizer Inc. significantly increased investment in artificial intelligence (AI) across its discovery,…
Is Biopharma’s $8.5 Billion AI Investment in 2025 Across Discovery, R&D, and Commercialization Shaping the 2026 Innovation Landscape?
Global – December 31, 2025 — Biopharmaceutical companies significantly increased investment in artificial intelligence (AI) in 2025, allocating…
Does Allarity Therapeutics’ Year-End Strategic Update Signal Renewed Momentum for Stenoparib in Hard-to-Treat Cancers?
Global – December 2025 — Allarity Therapeutics (NASDAQ: ALLR) has outlined key strategic and operational progress in its…
Is JPM 2026 the Moment Biopharma Finally Reset Its Strategy?
January 2026 — San Francisco | Global — The 44th Annual J.P. Morgan Healthcare Conference (JPM 2026) marked…
How Might Trump’s Strategic Healthcare Proposal Impact Innovation and Affordability?
January 22, 2026 — Global — BioNexAI Market Insights reports that U.S. President Donald J. Trump has introduced…
